NCT05605509View on ClinicalTrials.gov

RP-6306 in Patients With Advanced Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Advanced Cancer
Interventions
DRUG

RP-6306

Dose and schedule will be assigned at enrolment

DRUG

Gemcitabine

Dose and schedule will be assigned at enrolment

DRUG

FOLFIRI Protocol

Irinotecan Leucovorin FU

DRUG

Trastuzumab

standard doses q3weekly

DRUG

RP-3500

Dose and schedule will be assigned at enrolment

Trial Locations (6)

V1Y 5L3

BCCA - Kelowna, Kelowna

V5Z 4E6

BCCA - Vancouver, Vancouver

K7L 2V7

Kingston Health Sciences Centre, Kingston

N6A 5W9

London Health Sciences Centre Research Inc., London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

Sponsors

Collaborators (1)

Repare Therapeutics
All Listed Sponsors
collaborator

Repare Therapeutics

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK

NCT05605509 - RP-6306 in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter